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List of abbreviations in the order of appearance:  
HCV, hepatitis C virus; LT, liver transplantation; Peg-IFN, pegylated-interferon; SVR, 
sustained virological response; SVR12, sustained virological response at week 12 after the 
end of treatment; DAAs, direct-acting antiviral agents; LS, liver stiffness; kPa, kilopascal; 
EOT, end of therapy; IL28B, Interleukin 28B; HLA, human leukocyte antigen; AE, adverse 
event; AST, aspartate aminotransferase; APRI, AST to platelet ratio index; ALT, alanine 
aminotransferase; SVR24, sustained virological response at week 24 after the end of 
treatment; ROC, receiver operating characteristic; MELD, Model for End-stage Liver 
Disease; F, fibrosis; ITT, intention to treat.  
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ABSTRACT      
Background & Aims. Several studies have shown that new direct-acting-antivirals (DAAs) 
maintain their efficacy in liver transplant (LT) recipients with severe HCV recurrence. We 
determined the clinical impact of Sofosbuvir/Ribavirin in LT through the changes in liver 
function and fibrosis state at 24 and 48 weeks after treatment. 
Methods. Between 06/2014 and 07/2015, 126 patients (30 F3, 96 F4 Metavir stage) were 
enrolled to receive sofosbuvir+ribavirin (24 weeks, 118 patients) or 
sofosbuvir+simeprevir+ribavirin (12 weeks, 8 patients); treatment was initiated at a median 
time of 4.3 years from LT. Median follow-up after therapy completion was 461 days. 
Results. All 30 F3 patients achieved a sustained virological response at week 24 after 
treatment (SVR24), and showed a distinct amelioration of the AST-to-platelet-ratio-index 
(APRI), FIB-4 and liver stiffness at elastography by week 24 post-therapy, which were 
maintained at week 48. 
Of the 96 F4 cirrhotic patients, 72 (75%) achieved SVR24 accompanied by significant 
improvement of liver function, which was maintained at week 48 (Child B-C 22% baseline, 
11% week 24, 7% week 48); APRI, FIB-4, liver stiffness further improved significantly 
between week 24 and 48 of follow-up. Among the 77 responders (27 F3, 50 F4) who 
underwent elastography at baseline and at the end of follow-up, 39 (50.6%; 18 F3, 21 F4) 
exhibited a regression in fibrosis stage. Conclusion. At about one-year from the completion 
of successful sofosbuvir-based therapy, patients with post-LT HCV and severe fibrosis 
experienced a long-term liver function improvement accompanied by a regression of 
fibrosis stage in half of them.  
 
Keywords  
Liver transplantation; HCV recurrence; direct-acting antivirals; non-invasive fibrosis tests; 
survival. 
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Key point box  
• 126 patients with post liver transplant HCV and severe fibrosis (30 F3 and 96 F4 
Metavir) received a sofosbuvir-based antiviral therapy. The median follow-up after 
therapy was 461 days.  
• All the 30 F3 patients and 72 of the 96 cirrhotics (75%) achieved a sustained 
virological response at week 24 after treatment. 
• HCV-eradicated patients showed a distinct amelioration in AST-to-platelet-ratio-
index, FIB-4 and liver stiffness at week 24 after therapy, which persisted in F3 
patients and further improved in F4 ones at week 48.  
• In transient elastography, the fibrosis stage regressed in half of the HCV-eradicated 
patients at week 48 after therapy.  
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INTRODUCTION 
Hepatitis C virus (HCV) is the leading cause of cirrhosis and hepatocellular carcinoma and  
the most common indication for liver transplantation (LT) in Europe and United States [1]. 
Infection recurs almost universally in patients who have detectable serum HCV RNA at LT 
and it is the main cause of graft failure and patient death [2]. Successful HCV eradication 
is associated with reduced disease progression, and improved liver allograft and recipient 
survival [3].  
Until few years ago, pegylated-interferon (Peg-IFN) with ribavirin was the only treatment 
for HCV recurrence post-LT; however its use was limited by poor efficacy and beset with 
significant adverse events [4]. The addition of first generation protease inhibitors, 
boceprevir and telaprevir, doubled the rates of sustained virological response (SVR) at 12 
weeks (SVR12) in HCV genotype 1, but was aggravated by unacceptable toxicity and 
drug-drug interactions [5]. A major breakthrough has been the advent of second generation 
direct-acting antiviral agents (DAAs), which interact with different HCV functions and have 
markedly improved antiviral efficacy and tolerability [6], leading to HCV eradication also in 
patients with severe recurrent hepatitis C after LT.  
The therapeutic potential of the prototype sofosbuvir was quickly perceived; the 
combinations of sofosbuvir with ribavirin ± Peg-IFN and of sofosbuvir with simeprevir ± 
ribavirin were reported in early international studies to achieve 59% to 88% SVR12 rates 
[7, 8]. A sofosbuvir compassionate use program was activated in Italy between June 2014 
and December 2014; simeprevir became available later, in February 2015. 
The primary target of early studies was the virologic efficacy and the tolerability of DAAs in 
order to meet the urgent demand from transplant patients. In this single-center study, we 
report the clinical outcome of therapy in a large series of patients with severe fibrosis due 
to hepatitis C recurrence; the majority were treated with sofosbuvir plus ribavirin, a minority 
with sofosbuvir plus simeprevir plus ribavirin. We focused on the changes in liver function 
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parameters and in non-invasive tests of fibrosis up to 48 weeks after the end of successful 
treatment. 
 
PATIENTS AND METHODS 
Study population 
Out of 273 surviving HCV recipients with persistent viremia following LT performed in Turin 
(Italy) since January 2000, between June 2014 and May 2015 we enrolled 126 patients 
with recurrent hepatitis C who exhibited a Metavir staging score ≥3, and a creatinine 
clearance ≥30 mL/min. The severity of fibrosis was determined within 6 months from 
treatment by liver biopsy or by transient elastography [liver stiffness (LS) cut-off values of 
9.5 kilopascal (kPa) and 12.5 kPa corresponding, respectively, to Metavir F3 and F4 
fibrosis stages] [9]. Only transient elastography measurements with a success rate of at 
least 60% were considered valid. 
From June 2014 to December 2014 patients were treated in the context of the sofosbuvir 
national compassionate use program; each treatment was approved by the local ethic 
committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di 
Torino—A.O. Ordine Mauriziano—A.S.L. TO1) and the patients provided written informed 
consent. By the Italian legislation, Regional Transplantation Centers are the lawful 
custodians of the recipient/donor biomedical data for clinical and for research purposes. All 
study procedures were compliant with the ethical standards of the 2000 Declaration of 
Helsinki as well as the Declaration of Istanbul 2008.                                                                                                                                               
The demographic and baseline characteristics of the study population and their donors are 
shown in Table 1. 
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Study protocol 
The treatment regimens consisted of sofosbuvir 400 mg once daily and ribavirin twice daily 
(at a dose of 1000 mg daily with body weight <75 kg, or 1200 mg daily with body weight 
≥75 kg, adjusted according to haemoglobin level and renal function) for 24 weeks, or 
sofosbuvir 400 mg once daily, ribavirin twice daily (weight-based) and simeprevir 150 mg 
once daily for 12 weeks. Epoetin-alfa at 20,000-40,000 units/week was administered 
subcutaneously to patients with haemoglobin levels <10 g/dL. 
Patients underwent clinical and laboratory assessment [HCV RNA by polymerase chain 
reaction technique with AmpliPrep®/COBAS TaqMan® HCV version 2 (Roche Molecular 
Systems, Inc., Branchburg, NJ, US), complete blood cell count, liver and kidney function 
tests, serum electrolytes, serum levels of immunosuppressive drugs] at baseline, weekly 
for the first month, then monthly while on treatment and at 1, 3, 6 and 12 months after the 
end of therapy (EOT). No viral resistance monitoring was performed. 
At baseline, all patients were tested for HCV genotype (reverse hybridization line probe 
assay, INNO-LIPA, Innogenetics, Ghent, Belgium), Interleukin 28B (IL28B) rs12979860 
C/T and rs8099917 T/G polymorphisms (Custom TaqMan® Allelic Discrimination Kit, Life 
Technologies Applied Biosystems®, Thermo Fisher Scientific, Waltham, MA, US) and 
serum 25-OH vitamin D level (fully automated chemiluminescence immunoassay, ADVIA 
Centaur® Vitamin D Total assay, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, 
USA). Human leukocyte antigen (HLA) DRB1 typing was collected as well (performed 
before transplant, by serology methods until 2006 and then by molecular low-resolution), 
paying particular attention to HLA-DRB1*11 phenotype [10]. Adverse events (AE), drug 
dose modifications, use of growth factors, blood transfusions, and need for hospitalisation 
during treatment were recorded. 
To assess the changes in fibrosis evolution in virological responders, transient 
elastography was performed at 24 and 48 weeks from EOT. The FIB-4 index and the 
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aspartate aminotransferase (AST) to platelet ratio index (APRI) were calculated at baseline 
and 24 and 48 weeks after EOT on fasting blood samples. The following formulas were 
used. FIB-4=[age (years) x AST (IU/L)]/[platelets (109/L) x alanine aminotransferase 
(ALT)1/2 (IU/L)]; a score of <1.45 and >3.25 should identify patients who, respectively, have 
moderate or significant fibrosis [11]. APRI=[AST (IU/L)/upper limit of normal (IU/L)] x 
100/platelets (109/L); severe fibrosis was considered unlikely with an APRI ≤0.7 and 
cirrhosis likely with an APRI ≥1 [12]. Upper limits of normal for our laboratory are: ALT 40 
IU/L for male and 35 IU/L for female; AST 45 IU/L for male and 30 IU/L for female. 
Survival data were collected on May 31, 2016. 
 
Study endpoints 
Primary endpoints of the study were survival and clinical outcome of patients who had 
achieved a sustained virological response at week 24 after EOT (SVR24). To this purpose 
we considered the variations from baseline to weeks 24 and 48 of: i) liver function 
parameters; ii) non-invasive tests of fibrosis (APRI, FIB-4, transient elastography). 
Secondary endpoint was the safety of antiviral therapy.  
 
Statistical analysis 
Categorical variables were represented as n (%) and compared using Fisher’s exact test. 
Quantitative variables were shown as median (25th - 75th percentiles) and were compared, 
as appropriate, by t-test (parametric data), by Mann-Whitney U test (non parametric, 
unpaired data) or by Wilcoxon signed-rank test (non parametric, paired data). Receiver 
operating characteristic (ROC) curve analyses were performed to obtain the best possible 
Model for End-stage Liver Disease (MELD) and Child scores, in order to identify 
beforehand those patients who achieved SVR24. Data elaboration was performed using 
Page 9 of 49 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Prism® version 6 (GraphPad Software Inc., La Jolla, CA, US)and IBM SPSS version 21 
(New York, NY, US). 
 
RESULTS  
Of the 126 patients who entered the study, 118 received sofosbuvir and ribavirin for 24 
weeks and 8 were treated with sofosbuvir, simeprevir and ribavirin for 12 weeks. In the 
former group, 116 completed the full course of therapy; 2 patients died while on treatment 
(on day 93 and 151), 4 following the EOT (on day 41, 143, 166 and 328). The median 
follow-up of the surviving patients after EOT was 461 days (range 278-515 days). 
All patients except 1 were Caucasian. Forty-seven percent of the grafts came from donors 
≥65 year old and/or with macrovesicular steatosis ≥15% (suboptimal graft) [13], 8% from 
hepatitis B core antibody positive and 7.1% from HCV antibody positive donors. 
Two patients had been treated with a first-generation HCV protease-inhibitor before LT.                               
The baseline stage of hepatic fibrosis (F) was evaluated in 28 patients by liver biopsy 
according to Metavir score (3 F3, 25 F4), in 12 patients by combined liver biopsy and 
transient elastography (12 F4) and in 86 patients by transient elastography only (27 F3 
and 59 F4). The median LS was: 11 kPa [interquartile 10.1-12] in the F3 group and 21.8 
kPa [17-34.8] in the F4 group. Thirty-four patients had diabetes mellitus, 33 were insulin 
dependent at the beginning of antiviral therapy.  
The 8 patients treated with sofosbuvir, simeprevir and ribavirin were immunosuppressed 
with tacrolimus. The HCV genotype was 1a in two and 1b in six. Seven patients had 
fibrosis Metavir F3 and 1 F4 (Child A5, MELD 7), with median HCV RNA 6.56 log10 IU/mL.  
Further demographic and baseline characteristics are presented in Table 1. 
Four weeks after antiviral therapy was started, a statistically significant decrease was 
observed in the AST and ALT median values from 67 IU/L [45-114] to 24 IU/L [18-33], p 
<0.001, and 58 IU/L [40-100] to 18 IU/L [13-26], p <0.001, respectively. Transaminase 
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values normalized (Figure S1) and remained normal throughout the follow-up in all 
eradicated patients but nine, who had persistently elevated enzymes (less than twice 
upper limit of normal). Six of these latter patients underwent a liver biopsy which showed 
minimal histological changes without evidence of rejection.  
The overall SVR24 rate was 81.0% (102/126 patients, 95% confidence interval 73.2-86.9) 
by intention to treat (ITT) analysis. The SVR24 rate was significantly higher in F3 
compared with F4 patients (30/30, 100% vs 72/96, 75%, p=0.001); in patients tolerating 
≥80% of the full weight-based ribavirin dose (n=104) compared with those tolerating <80% 
of the dose (n=22) (85.6% vs 59.0%, p=0.01) and in patients with preserved liver function 
(MELD ≤11 and Child ≤A6, according to ROC curves) (Figure S2). 
Two cirrhotic patients who became HCV RNA negative on therapy, died for multiresistant 
bacteria-related septic shock; two others died of liver failure after the EOT: one, 68 years 
old, had achieved a sustained virological response at week 4 after EOT, the other, 44 
years old, had achieved SVR12 and was on the list for retransplantation.  
Twenty patients experienced a relapse of HCV (17 at week 4, 2 at week 12 and 1 at week 
24 of follow-up; the latter cleared HCV RNA at week 4 on therapy and normalized 
transaminases at week 1). All relapsers were cirrhotic (9 patients Child A, 10 Child B and 1 
Child C). They had a median pre-treatment MELD of 13 and had received sofosbuvir and 
ribavirin; the majority of them were IL28B non-C/C genotype (80%) and experienced to 
previous antiviral therapy (65%) (Tables S1 and S2). Basal median LS was 28.0 kPa in 
the relapsers and 20.4 kPa in the cirrhotics who achieved viral eradication (p=0.01). APRI 
and FIB-4 were significantly higher in relapsers compared with responders at baseline 
(3.27 vs 1.92 and 8.45 vs 5.95, respectively; p <0.01 for both) (Table 2). 
From baseline to EOT, the median Child improved in relapsers from B7 to A6 (p=0.014), 
while the median MELD remained 13. Two patients died at 138 and 160 days after relapse 
due to progressive end-stage liver disease. Seventeen patients started a second treatment 
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course, at a median of 17 weeks (range 5-43 weeks) from the relapse. No significant 
variation in liver function tests was observed between relapse and retreatment. One 
patient refused retreatment. 
Overall, in the cirrhotic group, 20 patients (20.8%) had a stable MELD from baseline to the 
last available follow-up visit and 43 (44.8%) improved the score of at least 1 point; 46 
patients (47.9%) had a stable Child and 35 (36.5%) improved the score of at least 1 point. 
 
Clinical outcomes in patients who achieved viral eradication 
In the F3 patients, liver and kidney function remained normal (Table S3). APRI and FIB-4 
were significantly lower at week 24 after EOT, compared with pre-treatment median values 
(1.07 to 0.41, p <0.001, and 3.26 to 2.08, p <0.001, respectively); these indexes remained 
stable in the 28 patients who reached 48 weeks of follow-up (Figure 1, Panels A and C). 
LS (available in 27 patients) improved from 11.0 kPa [10.1-12.0] to 7.7 kPa [6.6-10.2], p 
<0.001, at week 24 and remained stable at week 48 (7.8 kPa [7.0-10.6], p=0.65 vs week 
24) (Figure 2, Panel A). In 18 patients (66.7%) LS decreased below the 9.5 kPa cut-off for 
F3 at week 48. 
At week 24 after EOT, the 72 F4 patients who had eradicat d HCV, exhibited a significant 
improvement in platelets count, bilirubin and albumin levels, degree of ascites and Child 
score at pair wise comparison with baseline values [the rate of Child A was 77.8% (56/72) 
at baseline and 88.9% (64/72) at week 24 of follow-up]; kidney function and MELD score 
did not vary. Seventy-one of the 72 responders reached 48 weeks of follow-up and 
showed a further significant increase in platelets count; albumin, ascites, and Child score 
[93% (66/71) Child A] remained stable (Table 3).  
Both APRI and FIB-4 decreased significantly at week 24 after EOT compared with baseline 
values (1.92 to 0.55, p <0.001, and 5.95 to 3.15, p <0.001, respectively), and further 
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decreased at week 48, compared with 24 week values (APRI 0.51, p <0.001; FIB-4 3.12, p 
<0.001) (Figure 1, Panels B and D). Fifty-one of the 72 patients underwent transient 
elastography at baseline and at SVR24; the median LS improved from 20.4 kPa [16.0-
33.8] to 17.5 kPa [11.1-25.7], p <0.001 (Figure 2, Panel B). Fifty patients underwent 
transient elastography also at week 48 after EOT; the median LS (14.0 kPa [10.0-21.3]) 
significantly decreased compared with week 24 (p=0.001); in 21 of them (42%) the LS fell 
below the 12.5 kPa cut-off.  
In 39 (50.6%) of the 77 F3-F4 responders pooled together, the fibrosis stage had 
regressed in transient elastography by at least one Metavir stage at week 48 after EOT. 
No patients developed hepatocellular carcinoma in the period of observation. 
Thirteen out of the 20 cirrhotic responders with large oesophageal varices at baseline, 
underwent a second 48 week follow-up endoscopy; no change in the size of varices was 
observed. 
 
Safety  
AE are summarized in Table S4.  
During therapy, seven cirrhotic patients were hospitalised: two patients for grade 3 
encephalopathy, two for severe variceal bleeding and three for sepsis in decompensated 
liver disease. Six cirrhotic patients died of complications of end-stage liver disease, 
unrelated to antiviral therapy.  
Three patients discontinued ribavirin for less than 1 week due to diffuse macular skin rash 
and no one discontinued therapy permanently due to AE.  
Because of anemia and/or compromised renal function, 34.1% (43/126) of the patients 
were treated with a non weight-based escalating dose of ribavirin, starting from 400 mg 
daily and 11.1% (14/126) required dosage reduction; however, 82.5% (104/126) received 
at least 80% of the weight-based dosage. Median daily ribavirin dose was 1000 mg from 
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baseline to EOT and median haemoglobin level declined from 12.8 g/dL at baseline to 10.9 
g/dL at week 4 and remained stable around 10.8 g/dL from week 8 to week 24 (Figure 
S3). In 60 patients (47.6%) we measured at least one haemoglobin level of less than 10 
g/dL and in 12 (9.5%) of less than 8.5 g/dL; 45 patients (35.7%) received epoetin and 14 
(11.1%) required blood transfusion.  
Minimal dose adjustments in the calcineurin inhibitors were required throughout the 
treatment in 64% of the patients (27% increased, 12% decreased and 25% both 
decreased and increased the dose) to maintain stable trough levels. No biopsy-proven 
acute rejection occurred.  
 
DISCUSSION 
The advent of highly effective and well tolerated DAAs against the HCV is revolutionizing 
the outcome of LT for hepatitis C. In this setting, early treatment after surgery is expected 
to be the most cost-effective strategy for patients who are still viremic at LT [10, 14], 
nevertheless DAAs are providing rescue also to residual cohorts of re-infected transplant 
recipients who developed advanced HCV disease [7, 8, 15]. When sofosbuvir became 
available in Italy in June 2014, these patients received priority access to the new therapy 
through a compassionate use program. A majority were treated with sofosbuvir and 
ribavirin; a small minority received the combination of sofosbuvir, ribavirin and simeprevir, 
which became available almost at the end of the enrollment period. 
After a median follow-up of 461 days from EOT, 102 (81%) of our 126 patients are free of 
HCV and clinically stable. SVR was obtained also in a high proportion (95%) of the 21 
patients with genotype 3, though this genotype is the most difficult to treat in the ordinary 
clinical context. All treatment failures, excluding deceased patients, were due to virologic 
relapses and all relapses, except one, occurred within the first 12 weeks after EOT. 
Response to therapy was influenced by the stage of fibrosis and by intolerance to ribavirin: 
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75% of the patients with cirrhosis achieved an SVR compared to 100% of those with F3 
fibrosis and among the 22 patients who tolerated less than 80% of the optimal ribavirin 
dosage, only 59% obtained an SVR. As expected, anemia was the main complication of 
ribavirin.  
Considering the higher proportion of patients with cirrhosis in this study, our results appear 
better than the 70% rate of SVR12 reported by Charlton [16] in a smaller series of 40 
patients recruited in a multicenter study, of whom only 40% were cirrhotics; possibly the 
management of the patients in a single center adopting a common approach may lead to 
more uniform results. Though our results are distinctly better than the 43% response 
reported by Forns et al [7], their series included a mixed population of compensated and 
decompensated cirrhotics in which a substantial number of patients had a higher MELD 
score and more severe disease than our patients.  
There were in our study six deaths due to complications of the liver disease, two occurring 
in patients who had cleared the HCV. The deceased patients had a higher MELD score, 
ranging from 14 to 19, in confirmation that a deteriorated liver function may prevent clinical 
improvement despite the antiviral efficacy of treatment [17]; vice versa a preserved liver 
function expressed by a Child Pugh score ≤6 and a MELD ≤11 was associated with SVR.  
In our 72 cirrhotic responders, SVR24 was associated with the normalization of 
aminotransferases in almost all patients, accompanied by a decrease of bilirubin and an 
increase of albumin levels; renal function deteriorated in none and ascites disappeared in 
three quarters of cases. The platelet count increased throughout therapy, presumably 
related to the administration of epoetin and to an increased production of endogenous 
erythropoietin, secondary to ribavirin-induced anemia [18]. The platelet number diminished 
to baseline values at week 12 post-therapy, but then climbed back significantly at week 24 
and further increased at week 48; this trend and the regression of ascites might be 
expression of an initial reduction in portal hypertension.     
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The APRI and FIB-4 indexes significantly improved throughout the follow-up; as 
aminotransferases and platelets are major components for their calculation, the 
improvement can be explained by the normalization of the enzymes and by the increase in 
the platelet count.  
LS values were significantly reduced at the 6th month of follow-up; this early improvement 
presumably resulted for a large extent from the decrease of inflammation and edema 
which may artificially alter elastography. Interestingly, however, LS values showed a further 
significant decrease during the subsequent 6 month follow-up in patients with cirrhosis. 
Considering that artefacts due to liver inflammation could no longer be implicated, it is 
plausible that the observed continuing decrease of LS after the SVR24 corresponded to a 
genuine progressive reduction of fibrosis. In agreement with previous findings of fibrosis 
reversion in non-transplant patients with HCV cirrhosis who responded to interferon-
therapy [19-21], our data would suggest that regression of fibrosis starts early and may 
become already measureable by transient elastography in the first year after therapy. 
In conclusion, our experience in a large single center LT cohort of advanced recurrent HCV 
disease, confirms the major therapeutic impact of sofosbuvir with ribavirin, extending also 
to difficult-to-treat genotype 3 patients. 
We acknowledge that a new wave of more efficacious DAA combinations is now available 
to treat hepatitis C [8, 15, 22]. Nevertheless, this study provides a paradigm of the 
excellent clinical outcome and of the potential for disease reversibility after successful DAA 
therapy in the transplant setting.  
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Table 1. Demographic and baseline characteristics of recipients and donors  
Recipient features (N=126) 
Age (years) 60 [54-66] 
Male 99 (78.6%) 
Body Mass Index (Kg/m
2
) 24.6 [22.5–26.9] 
25-OH vitamin D^ (<20 ng/mL) 71 (59.2%) 
HLA-DRB1*11 positive phenotype 34 (27.0%) 
IL28B genotype 
rs 12979860 C/C 
rs 8099917 T/T 
 
32 (25.4%) 
59 (46.8%) 
Previous antiviral treatment 
    Antiviral treatment after LT 
83 (65.9%) 
57 (45.2%) 
Immunosuppressive drug 
CsA – Tac – MMF – other 
 
50 (39.7%) – 56 (44.4%) – 56 (44.4%) – 5 (4.0%) 
Time since LT (years) 4.3 [2.3–7.2] 
HCV genotype 
1a - 1b - 1 (unspecified) 
2 - 3 – 4 
 
17 (13.5%) – 70 (55.6%) – 6 (4.8%) 
6 (4.8%) – 21 (16.7%) – 6 (4.8%) 
Baseline HCV RNA (log10 IU/mL) 
≥ 10
6
 IU/mL 
6.40 [6.10–6.66] 
101 (80.2%) 
Corresponding Metavir fibrosis stage 
F3 – F4 
 
30 (23.8%) – 96 (76.2%) 
Haemoglobin (g/dL) 12.8 [11.4–14.4] 
Platelets count (10
9
/L) 99 [67-140] 
Liver enzymes (IU/L) 
Aspartate aminotransferase 
Alanine aminotransferase 
γ-Glutamyltransferase 
 
60 [40-101] 
69 [45-116] 
75 [41-152] 
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Total bilirubin (mg/dL) 1.1 [0.7–1.8] 
INR 1.07 [0.98–1.22] 
Albumin (g/dL) 3.9 [3.6–4.3] 
eGFR* (mL/min) 70 [54-87] 
MELD score
§
 10 [8-13] 
Child class
§
 A – B – C 65 (67.7%) – 27 (28.1%) – 4 (4.2%) 
Ascites
§
 38 (39.6%) 
Encephalopathy
§
 12 (12.5%) 
Presence of varices
§
 26 (27.1%) 
Donor features (N=126) 
Age (years) 62 [50–71] 
Male 69 (54.8%) 
Split liver graft 2 (1.6%) 
Graft quality^
 
suboptimal
#
 57 (47.5%) 
Cold ischemia time (minutes) 486 [424–545] 
Donor/Recipient match 
D-MELD 982 [666–1303] 
 
Numerical variables are expressed as median [Q1-Q3]                                                                                       
Categorical variables are expressed as numbers (prevalence, %) 
^6 missing data 
*Chronic Kidney Disease Epidemiology Collaboration equation 
§
In 96 cirrhotic patients 
#
According to Salizzoni et al, Transpl Int 2003 
Abbreviations: CsA, cyclosporine; D-MELD, donor age x recipient MELD; eGFR, estimated glomerular 
filtration rate; F, fibrosis; HCV, hepatitis C virus; HLA, human leukocyte antigen; IL28B, Interleukin 28B; LT, 
liver transplantation; MELD, Model for End-stage Liver Disease; MMF, mycophenolate mofetil; Tac, 
tacrolimus.  
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Table 2. Liver function tests and non-invasive markers of fibrosis at baseline and at 
the end of therapy in responder versus relapser cirrhotic patients 
 
BASELINE 
Responders  
(n=72) 
Relapsers  
(n=20) 
p
#
 
APRI 1.92 [1.00-3.27] 3.27 [1.72-5.51] 0.007 
FIB-4 5.95 [3.60-11.10] 8.45 [7.17-16.08] 0.009 
Liver stiffness* (kPa) 20.4 [16.0-33.8] 28.0 [21.6–44.4] 0.01 
Child score 5 [5-6] 7 [6-8] 0.002 
MELD score 10 [8-12] 13 [9-16] 0.02 
    
EOT 
Responders  
(n=72) 
Relapsers  
(n=20) 
p
#
 
APRI 0.46 [0.29-0.76] 0.83 [0.57-1.22] 0.02 
FIB-4 3.25 [1.90-4.30] 4.80 [3.71-7.42] 0.01 
Liver stiffness* (kPa) 17.5 [11.1-25.7] 23.4 [18.3-39.0] 0.09 
Child score 5 [5-6] 6 [5-7] 0.19 
MELD score 11 [9-14] 13 [11-17] 0.05 
Numerical variables are expressed as median [Q1-Q3] 
*Liver stiffness was available at baseline in 51 responders and 17 relapsers; at EOT in 51 responders and 13 
relapsers 
#
p-values calculated according to Wilcoxon test for paired data 
Abbreviations: APRI, AST to platelet ratio index; EOT, end of therapy; kPa, kilopascal; MELD, Model for End-
stage Liver Disease. 
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Table 3. Clinical and biochemical variations in long-term responder cirrhotic patients 
 
Baseline 
(N=72) 
EOT 
(N=72) 
SVR12 
(N=72) 
SVR24 
(N=72) 
SVR48 
(N=71°) 
p^ p
§
 
AST (IU/L) 69 [47-97] 23 [20-28] 27 [22-35] 24 [18-32] 21 [18-28] <0.001 0.13 
ALT (IU/L) 59 [41-90] 15 [11-23] 18 [14-27] 16 [12-25] 17 [12-27] <0.001 0.02 
Bilirubin (mg/dL) 1.1 [0.8-1.5] 1.4 [1.1-2.2] 0.9 [0.6-1.2] 0.8 [0.6-1.2] 0.9 [0.6-1.1] <0.001 0.74 
INR 
1.06                     
[0.99-1.20] 
1.11            
[1.07-1.24] 
1.09        
[1.02-1.24] 
1.08          
[1.02-1.22] 
1.11       
[1.07-1.23] 
0.03 0.007 
Albumin (g/dL) 3.9 [3.6-4.3] 4.1 [3.8-4.4] 4.1 [3.7-4.3] 4.2 [3.8-4.4] 4.3 [4.0-4.5] 0.02 0.31 
Creatinine (mg/dL) 1.1 [0.9-1.3] 1.1 [0.9-1.3] 1.0 [0.9-1.3] 1.1 [1.0-1.3] 1.1 [0.9-1.3] 0.36 0.12 
eGFR* (mL/min) 68 [52-84] 64 [52-80] 67 [53-83] 63 [52-78] 62 [52-82] 0.26 0.25 
Platelets (10
9
/L) 99 [65-134] 131 [86-185] 99 [64-133] 108 [72-142] 112 [68-144] 0.002 0.01 
Ascites 22 (30.6%) 12 (16.7%) 8 (11.1%) 7 (9.7%) 7 (9.9%) 0.003 >0.99 
Encephalopathy 5 (6.9%) 4 (5.6%) 3 (4.2%) 3 (4.2%) 2 (2.8%) 0.72 >0.99 
MELD score 10 [8-12] 11 [9-14] 9 [8-11] 9 [8-11] 10 [8-11] 0.34 0.92 
Child score 5 [5-6] 5 [5-6] 5 [5-6] 5 [5-5] 5 [5-5] <0.001 0.68 
Numerical variables are expressed as median [Q1-Q3]                                                                                    
Categorical variables are expressed as numbers (prevalence,%) 
p-values calculated according to Wilcoxon test for paired data for numerical variables and according to 
Fisher’s exact test for categorical variables 
°71 out of 72 cured patients reached 48 weeks of follow-up after therapy 
*Chronic Kidney Disease Epidemiology Collaboration equation 
^Baseline versus SVR24 
§
SVR24 versus SVR48 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular 
filtration rate; EOT, end of therapy; MELD, Model for End-stage Liver Disease; SVR12, sustained virological 
response at week 12 after end of therapy; SVR24, sustained virological response at week 24 after end of 
therapy; SVR48, sustained virological response at week 48 after end of therapy. 
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FIGURE LEGENDS 
Figure 1. Variations of APRI (Panels A and B) and FIB-4 (Panels C and D) from 
baseline to weeks 24 and 48 after therapy, in F3 and F4 long-term responders. APRI, 
AST to platelet ratio index; F, fibrosis according to Metavir; SVR24, sustained virological 
response at week 24 after therapy; SVR48, sustained virological response at week 48 after 
therapy. 
 
Figure 2. Variations of liver stiffness from baseline to weeks 24 and 48 after therapy 
in F3 (Panel A) and F4 (Panel B) long-term responders. F, fibrosis according to Metavir; 
kPa, kilopascal; SVR24, sustained virological response at week 24 after therapy; SVR48, 
sustained virological response at week 48 after therapy. 
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List of abbreviations in the order of appearance:  
HCV, hepatitis C virus; LT, liver transplantation; Peg-IFN, pegylated-interferon; SVR, 
sustained virological response; SVR12, sustained virological response at week 12 after the 
end of treatment; DAAs, direct-acting antiviral agents; LS, liver stiffness; kPa, kilopascal; 
EOT, end of therapy; IL28B, Interleukin 28B; HLA, human leukocyte antigen; AE, adverse 
event; AST, aspartate aminotransferase; APRI, AST to platelet ratio index; ALT, alanine 
aminotransferase; SVR24, sustained virological response at week 24 after the end of 
treatment; ROC, receiver operating characteristic; MELD, Model for End-stage Liver 
Disease; F, fibrosis; ITT, intention to treat. AUC, area under the curve. 
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ABSTRACT     
Background & Aims. Several studies reporthave shown that the new direct-acting-antivirals 
(DAAs) induce maintain viral their efficacyeradication also in liver transplant (LT) recipients 
with severe HCV recurrence. We determined The the clinical impact of 
Sofosbuvir/Ribavirin in LT therapy through the changes in on liver function and on fibrosis 
progressionstate at 24 and 48 weeks after treatmentwas evaluated. 
Methods. Between 06/2014 and 07/2015, 126 patients (30 F3, 96 F4 Metavir stage) were 
enrolled to receive sofosbuvir+ribavirin (24 weeks, 118 patients) or 
sofosbuvir+simeprevir+ribavirin (12 weeks, 8 patients); treatment was initiated at a median 
time of 4.3 years from LT. Median follow-up after therapy completion was 461 days. 
Results. All 30 F3 patients achieved a sustained virological response at week 24 after 
treatment (SVR24), and showed a distinct amelioration of the AST-to-platelet-ratio-index 
(APRI), FIB-4 and liver stiffness at elastography by week 24 post-therapy, which were 
maintained at week 48. 
Of the 96 F4 cirrhotic patients, 72 (75%) achieved SVR24 accompanied by a significant 
improvement of liver function, which was maintained at week 48 (Child B-C 22% baseline, 
11% week 24, 7% week 48); APRI, FIB-4, and liver stiffness further improved significantly 
between week 24 and 48 of follow-up. Among the 77 responders (27 F3, 50 F4) who 
underwent elastography at baseline and at the end of follow-up, 39 (50.6%; 18 F3, 21 F4) 
exhibited a regression in fibrosis stage. Conclusion. At about one-year from the completion 
of successful sofosbuvir-based therapy, patients with post-LT HCV and severe fibrosis 
experienced a long-term liver function improvement accompanied by a regression of 
fibrosis stage in half of them.  
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Keywords  
Liver transplantation; HCV recurrence; direct-acting antivirals; non-invasive fibrosis tests; 
survival. 
 
Key point box  
• 126 patients with post liver transplant HCV and severe fibrosis (30 F3 and 96 F4 
Metavir) received a sofosbuvir-based antiviral therapy. The Mmedian follow-up after 
therapy was 461 days.  
• All the 30 F3 patients and 72/96 72 of the 96 (75%) cirrhotics (75%) are currently 
alive and achieved a sustained virological response at week 24 after treatment. 
• HCV-eradicated cured patients showed a distinct amelioration in AST-to-platelet-
ratio-index, FIB-4 and liver stiffness at week 24 after therapy, which persisted in F3 
patients and further improved in F4 ones at week 48.  
• In transient elastography, the fibrosis stage regressed in half of the HCV-eradicated 
Overall, a fibrosis stage regression evaluated by transient elastography, occurred in 
half of the patients at week 48 after therapy.  
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INTRODUCTION 
Hepatitis C virus (HCV) is the leading cause of cirrhosis and hepatocellular carcinoma and  
the most common indication for liver transplantation (LT) in Europe and United States [1]. 
Infection recurs almost universally in patients who have detectable serum HCV RNA at LT 
and it is the main cause of graft failure and patient death [2]. Successful HCV eradication 
is associated with reduced disease progression, and improved liver allograft and recipient 
survival [3].  
Until few years ago, pegylated-interferon (Peg-IFN) with ribavirin was the only treatment 
for HCV recurrence post-LT; however its use was limited by poor efficacy and beset with 
significant adverse events [4]. The addition of first generation protease inhibitors, 
boceprevir and telaprevir, doubled the rates of sustained virological response (SVR) at 12 
weeks (SVR12) in HCV genotype 1, but was aggravated by unacceptable toxicity and 
drug-drug interactions [5]. A major breakthrough has been the advent of second generation 
direct-acting antiviral agents (DAAs), which interact with different HCV functions and have 
markedly improved antiviral efficacy and tolerability [6], leading to HCV eradication also in 
patients with severe recurrent hepatitis C after LT.  
The therapeutic potential of the prototype sofosbuvir was quickly perceived; the 
combinations of sofosbuvir with ribavirin ± Peg-IFN and of sofosbuvir with simeprevir ± 
ribavirin were reported in early international studies to achieve 59% to 88% SVR12 rates 
[7, 8]. A sofosbuvir compassionate use program was activated in Italy between June 2014 
and December 2014; simeprevir became available later, in February 2015. 
The primary target of early studies was the virologic efficacy and the tolerability of DAAs in 
order to meet the urgent demand from transplant patients. In this single-center study, we  
report the clinical outcome of therapy in a large series of patients with severe fibrosis due 
to hepatitis C recurrence; the majority were treated with sofosbuvir plus ribavirin, a minority 
with sofosbuvir plus simeprevir plus ribavirin. We focused  on the changes in liver function 
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parameters and in non-invasive tests of fibrosis up to 48 weeks after the end of successful 
treatment. These studies had short follow-ups and did not deal with the long-term clinical 
outcome of LT patients who had responded to therapy.  
In this single-center study, we collected a large series of patients with post-transplant 
severe fibrosis due to hepatitis C recurrence; the majority were treated with sofosbuvir plus 
ribavirin, a minority with sofosbuvir plus simeprevir plus ribavirin. We report the virologic 
results and focus on the changes observed in liver function parameters and in non-
invasive tests of fibrosis up to 48 weeks after the end of successful therapy. 
 
PATIENTS AND METHODS 
Study population 
Out of 273 surviving HCV recipients with persistent viremia following LT performed in Turin 
(Italy) since January 2000, between June 2014 and May 2015 we enrolled 126 patients 
with recurrent hepatitis C who exhibited a Metavir staging score ≥3, and a creatinine 
clearance ≥30 mL/min. The severity of fibrosis was determined within 6 months from 
treatment by liver biopsy or by transient elastography [liver stiffness (LS) cut-off values of 
9.5 kilopascal (kPa) and 12.5 kPa corresponding, respectively, to Metavir F3 and F4 
fibrosis stages] [9]. Only transient elastography measurements with a success rate of at 
least 60% were considered valid. 
From June 2014 to December 2014 patients were treated in the context of the sofosbuvir 
national compassionate use program; each treatment was approved by the local ethic 
committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di 
Torino—A.O. Ordine Mauriziano—A.S.L. TO1) and the patients provided written informed 
consent. By the Italian legislation, Regional Transplantation Centers are the lawful 
custodians of the recipient/donor biomedical data for clinical and for research purposes. All 
study procedures were compliant with the ethical standards of the 2000 Declaration of 
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Helsinki as well as the Declaration of Istanbul 2008.                                                                                                                                               
The demographic and baseline characteristics of the study population and their donors are 
shown in Table 1. 
 
Study protocol 
The treatment regimens consisted of sofosbuvir 400 mg once daily and ribavirin twice daily 
(at a dose of 1000 mg daily with body weight <75 kg, or 1200 mg daily with body weight 
≥75 kg, adjusted according to haemoglobin level and renal function) for 24 weeks, or 
sofosbuvir 400 mg once daily, ribavirin twice daily (weight-based) and simeprevir 150 mg 
once daily for 12 weeks. Epoetin-alfa at 20,000-40,000 units/week was administered 
subcutaneously to patients with haemoglobin levels <10 g/dL. 
Patients underwent clinical and laboratory assessment [HCV RNA by polymerase chain 
reaction technique with AmpliPrep®/COBAS TaqMan® HCV version 2 (Roche Molecular 
Systems, Inc., Branchburg, NJ, US), complete blood cell count, liver and kidney function 
tests, serum electrolytes, serum levels of immunosuppressive drugs] at baseline, weekly 
for the first month, then monthly while on treatment and at 1, 3, 6 and 12 months after the 
end of therapy (EOT). No viral resistance monitoring was performed. 
At baseline, all patients were tested for HCV genotype (reverse hybridization line probe 
assay, INNO-LIPA, Innogenetics, Ghent, Belgium), Interleukin 28B (IL28B) rs12979860 
C/T and rs8099917 T/G polymorphisms (Custom TaqMan® Allelic Discrimination Kit, Life 
Technologies Applied Biosystems®, Thermo Fisher Scientific, Waltham, MA, US) and 
serum 25-OH vitamin D level (fully automated chemiluminescence immunoassay, ADVIA 
Centaur® Vitamin D Total assay, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, 
USA). Human leukocyte antigen (HLA) DRB1 typing was collected as well (performed 
before transplant, by serology methods until 2006 and then by molecular low-resolution), 
paying particular attention to HLA-DRB1*11 phenotype [10]. Adverse events (AE), drug 
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dose modifications, use of growth factors, blood transfusions, and need for hospitalisation 
during treatment were recorded. 
To assess the changes in fibrosis evolution in virological responders, transient 
elastography was performed at 24 and 48 weeks from EOT. The FIB-4 index and the 
aspartate aminotransferase (AST) to platelet ratio index (APRI) were calculated at baseline 
and 24 and 48 weeks after EOT on fasting blood samples. The following formulas were 
used. FIB-4=[age (years) x AST (IU/L)]/[platelets (109/L) x alanine aminotransferase 
(ALT)1/2 (IU/L)]; a score of <1.45 and >3.25 should identify patients who, respectively, have 
moderate or significant fibrosis [11]. APRI=[AST (IU/L)/upper limit of normal (IU/L)] x 
100/platelets (109/L); severe fibrosis was considered unlikely with an APRI ≤0.7 and 
cirrhosis likely with an APRI ≥1 [12]. Upper limits of normal for our laboratory are: ALT 40 
IU/L for male and 35 IU/L for female; AST 45 IU/L for male and 30 IU/L for female. 
Survival data were collected on May 31, 2016. 
 
Study endpoints 
Primary endpoints of the study were survival and clinical outcome of patients who had 
achieved a sustained virological response at week 24 after EOT (SVR24). To this purpose 
we considered the variations from baseline to weeks 24 and 48 of: i) liver function 
parameters; ii) non-invasive tests of fibrosis (APRI, FIB-4, transient elastography). 
Secondary endpoint was the safety of antiviral therapy.  
 
Statistical analysis 
Categorical variables were represented as n (%) and compared using Fisher’s exact test. 
Quantitative variables were shown as median (25th - 75th percentiles) and were compared, 
as appropriate, by t-test (parametric data), by Mann-Whitney U test (non parametric, 
unpaired data) or by Wilcoxon signed-rank test (non parametric, paired data). Receiver 
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operating characteristic (ROC) curve analyses were performed to obtain the best possible 
Model for End-stage Liver Disease (MELD) and Child scores., and non-invasive fibrosis 
tests thresholds, in order to identify beforehand those patients who achieved SVR24. Data 
elaboration was performed using Prism® version 6 (GraphPad Software Inc., La Jolla, CA, 
US)and IBM SPSS version 21 (New York, NY, US). 
 
RESULTS  
Of the 126 patients who entered the study, 118 received sofosbuvir and ribavirin for 24 
weeks and 8 were treated with sofosbuvir, simeprevir and ribavirin for 12 weeks. In the 
former group, 116 completed the full course of therapy; 2 patients died while on treatment 
(on day 93 and 151), 4 following the EOT (on day 41, 143, 166 and 328). The median 
follow-up of the surviving patients after EOT was 461 days (range 278-515 days). 
All patients except 1 were Caucasian. Forty-seven percent of the grafts came from donors 
≥65 year old and/or with macrovesicular steatosis ≥15% (suboptimal graft) [13], 8% from 
hepatitis B core antibody positive donors and 7.1% from HCV antibody positive 
donorsones. 
Two patients had been treated with a first-generation HCV protease-inhibitor before LT.                               
The baseline stage of hepatic fibrosis (F) was evaluated in 28 patients by liver biopsy 
according to Metavir score (3 F3, 25 F4), in 12 patients by combined liver biopsy and 
transient elastography (12 F4) and in 86 patients by transient elastography only (27 F3 
and 59 F4). The median LS was: 11 kPa [interquartile 10.1-12] in the F3 group and 21.8 
kPa [17-34.8] in the F4 group. Thirty-four patients had diabetes mellitus, 33 were insulin 
dependent at the beginning of antiviral therapy.  
AllThe 8 patients treated with sofosbuvir, simeprevir and ribavirin were immunosuppressed 
with tacrolimus. The HCV genotype was 1a in two and 1b in six. Seven patients had 
fibrosis Metavir F3 and 1 F4 (Child A5, MELD 7), with median HCV RNA 6.56 log10 IU/mL.  
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Further demographic and baseline characteristics are presented in Table 1. 
Four weeks after antiviral therapy was started, a statistically significant decrease was 
observed in the AST and ALT median values from 67 IU/L [45-114] to 24 IU/L [18-33], p 
<0.001, and 58 IU/L [40-100] to 18 IU/L [13-26], p <0.001, respectively. Transaminase 
values normalized (Figure S1) and remained normal throughout the follow-up in all 
eradicated patients but nine, whose had persistently elevated enzymes transaminases 
persisted slightly elevated (less than twice upper limit of normal). Six of these latter 
patients underwent a liver biopsy which showed minimal histological changes without 
evidence of rejection. After 1 week of therapy, the median decrease in HCV RNA was 3.87 
log10 IU/mL in F3 and 3.55 log10 IU/mL in F4 group (p=0.002) (Figures S2 and S3).  
The overall SVR24 rate was 81.0% (102/126 patients, 95% confidence interval 73.2-86.9) 
by intention to treat (ITT) analysis (Figure 1). The SVR24 rate was significantly higher in 
F3 patients compared with F4 patients ones (30/30, 100% vs 72/96, 75%, p=0.001); and in 
patients tolerating ≥80% of the full weight-based ribavirin dose (n=104) compared with 
those tolerating <80% of the dose (n=22) (85.6% vs 59.0%, p=0.01) and in patients with 
preserved liver function (MELD ≤11 and Child ≤A6, according to ROC curves) (Figure S2). 
Two cirrhotic patients who became HCV RNA negative on therapy, died for multiresistant 
bacteria-related septic shock, two others died of liver failure after the EOT: one, 68 years 
old, had achieved a sustained virological response at week 4 after EOT, the other, 44 
years old, had achieved SVR12 and was on the list for retransplantation.  
Twenty patients experienced a relapsed of HCV (17 at week 4, 2 at week 12 and 1 at week 
24 of follow-up; the latter cleared HCV RNA at week 4 on therapy and normalized 
transaminases at week 1). All relapsers were cirrhotic (9 patients Child A, 10 Child B and 1 
Child C). They had a median pre-treatment MELD of 13 and had received sofosbuvir and 
ribavirin; a the majority of them were IL28B non-C/C genotype (80%) and experienced to 
previous antiviral therapy (65%) (Tables S1 and S2). Basal median LS was 28.0 kPa in 
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the relapsers and 20.4 kPa in the cirrhotics who achieved viral eradication (p=0.01). APRI 
and FIB-4 were significantly higher in relapsers compared with responders at baseline 
(3.27 vs 1.92 and 8.45 vs 5.95, respectively; p <0.01 for both) (Table 2). 
From baseline to EOT, their median Child improved in relapsers from B7 to A6 (p=0.014), 
while the median MELD remained 13. Two patients died at 138 and 160 days after relapse 
due to progressive end-stage liver disease. Seventeen patients started a second treatment 
course, at a median of 17 weeks (range 5-43 weeks) from the relapse. No significant 
variation in liver function tests was observed between relapse and retreatment.(Table S2). 
One patient refused retreatment. 
Two cirrhotic patients who were HCV RNA negative on therapy, died for multiresistant 
bacteria-related septic shock; 2 others died of liver failure after the EOT: one, 68 years old, 
had achieved a sustained virological response at week 4 after EOT, and one, 44 years old, 
had achieved SVR12 and was on the list for retransplantation.  
In the cirrhotic patients, significant predictors of SVR24 at univariate analysis (Figure 2) 
were MELD ≤11, Child ≤A6 and LS ≤26 kPa. The cut-offs were chosen according to ROC 
curves: area under the curve (AUC) for MELD 0.723, p=0.001; Child 0.759, p <0.001 and 
LS 0.751, p=0.002 (Figures S4 and S5).  
Basal median LS was 28.0 kPa in the relapsers and 20.4 kPa in the cirrhotics who 
achieved viral eradication (p=0.01). APRI and FIB-4 at baseline were significantly higher in 
relapsers compared with responders (3.27 vs 1.92 and 8.45 vs 5.95, respectively; p <0.01 
for both) (Table S3). 
Overall, in the cirrhotic group, between baseline and the last available follow-up, 20 
patients (20.8%) showed had a stable MELD from baseline to the last available follow-up 
visit and 43 (44.8%) improved the score of at least 1 point; 46 patients (47.9%) showedhad 
a stable Child and 35 (36.5%) improved the score of at least 1 point. 
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Clinical outcomes in patients who achieved viral eradication 
In the F3 patients, liver and kidney function remained normal (Table S34). APRI and FIB-4 
were significantly lower at week 24 after EOT, compared with pre-treatment median values 
(1.07 to 0.41, p <0.001, and 3.26 to 2.08, p <0.001, respectively); these indexes remained 
stable in the 28 patients who reached 48 weeks of follow-up (Figure 13, Panels A and C). 
LS (available in 27 patients) improved from 11.0 kPa [10.1-12.0] to 7.7 kPa [6.6-10.2], p 
<0.001, at week 24 and remained stable at week 48 (7.8 kPa [7.0-10.6], p=0.65 vs week 
24) (Figure 24, Panel A). In 18 patients (66.7%) LS decreased below the 9.5 kPa cut-off 
for F3 at week 48. 
At week 24 after EOT, the 72 F4 patients who had achieved viral eradicationeradicated 
HCV, showedexhibited a significant improvement in platelets count, bilirubin and albumin 
levels, degree of ascites and Child score at pair wise comparison with baseline values [the 
rate of Child A was 77.8% (56/72) at baseline and 88.9% (64/72) at week 24 of follow-up]; 
kidney function and MELD score did not vary. Seventy-one of the 72 responders reached 
48 weeks of follow-up and showed a further significant increase in platelets count; 
albumin, ascites, and Child score [93% (66/71) Child A] remained stable (Table 32).  
Both APRI and FIB-4 decreased significantly at week 24 after EOT compared with baseline 
values (1.92 to 0.55, p <0.001, and 5.95 to 3.15, p <0.001, respectively), and further 
decreased at week 48, compared with 24 week values (APRI 0.51, p <0.001; FIB-4 3.12, p 
<0.001) (Figure 13, Panels B and D). Fifty-one of the 72 patients underwent transient 
elastography at baseline and at SVR24; the median LS improved from 20.4 kPa [16.0-
33.8] to 17.5 kPa [11.1-25.7], p <0.001 (Figure 24, Panel B). Fifty patients underwent 
transient elastography also at week 48 after EOT; the median LS (14.0 kPa [10.0-21.3]) 
significantly decreased compared with week 24 (p=0.001); in 21 of them (42%) the LS fell 
below the 12.5 kPa cut-off.  
Page 36 of 49Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
As evaluated by transient elastography in F3-F4 patients pooled together, Inin 39 (50.6%) 
of the 77 (50.6%) F3-F4 responders pooled together, the fibrosis stage had regressed in 
transient elastography by at least one Metavir stage at week 48 after EOT. 
No patients developed hepatocellular carcinoma in the period of observation. 
Thirteen out of the 20 cirrhotic responders with large oesophageal varices at baseline, 
underwent a second 48 week follow-up endoscopy; no change in the size of varices was 
observed. which showed no changes. 
 
Safety  
AE are summarized in Table S45.  
During therapy, seven cirrhotic patients were hospitalised: two patients for grade 3 
encephalopathy, two for severe variceal bleeding and three for sepsis in decompensated 
liver disease. Six cirrhotic patients died of complications of end-stage liver disease, 
unrelated to antiviral therapy.  
Three patients discontinued ribavirin for less than 1 week due to diffuse macular skin rash 
and no one discontinued therapy permanently due to AE.  
Because of anemia and/or compromised renal function, 34.1% (43/126) of the patients 
were treated with a non weight-based escalating dose of ribavirin, starting from 400 mg 
daily and 11.1% (14/126) required dosage reduction; however, 82.5% (104/126) received 
at least 80% of the weight-based dosage. Median daily ribavirin dose was 1000 mg from 
baseline to EOT and median haemoglobin level declined from 12.8 g/dL at baseline to 10.9 
g/dL at week 4 and remained stable around 10.8 g/dL from week 8 to week 24 (Figure 
S36). In 60 patients (47.6%) we measured at least one haemoglobin level of less than 10 
g/dL and in 12 (9.5%) of less than 8.5 g/dL; 45 patients (35.7%) received epoetin and 14 
(11.1%) required blood transfusion.  
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Minimal dose adjustments in the calcineurin inhibitors were required throughout the 
treatment in 64% of the patients (27% increased, 12% decreased and 25% both 
decreased and increased the dose) to maintain stable trough levels. No biopsy-proven 
acute rejection occurred.  
 
DISCUSSION 
The advent of highly effective and well tolerated DAAs against the HCV is revolutionizing 
the outcome of LT for hepatitis C. In this setting, early treatment after surgery is expected 
to be the most cost-effective strategy for patients who are still viremic at LT [10, 14], 
nevertheless DAAs are providing rescue also to residual cohorts of re-infected transplant 
recipients who developed advanced HCV disease [7, 8, 15]. When sofosbuvir became 
available in Italy in June 2014, these patients received priority access to the new therapy 
through a compassionate use program. A majority were treated with sofosbuvir and 
ribavirin; a small minority received the combination of sofosbuvir, ribavirin and simeprevir, 
which became available almost at the end of the enrollment period. 
After a median follow-up of 461 days from EOT, 102 (81%) of our 126 patients are free of 
HCV and clinically stable. SVR was obtained also in a high proportion (95%) of the 21 
patients with genotype 3, though this genotype is the most difficult to treat in the ordinary 
clinical context. All treatment failures, excluding deceased patients, were due to virologic 
relapses and all relapses, except one, occurred within the first 12 weeks after EOT. 
Response to therapy was independent from gender, HCV genotype, basal viremia, rapid 
virologic response, HLA DRB1*11 phenotype and IL28B polymorphisms, while it was 
influenced by the stage of fibrosis and by intolerance to ribavirin: 75% of the patients with 
cirrhosis achieved an SVR compared to 100% of those with F3 fibrosis and among the 22 
patients who tolerated less than 80% of the optimal ribavirin dosage, only 59% obtained an 
SVR. As expected, anemia was the main complication of ribavirin.  
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Considering the higher proportion of patients with cirrhosis in this study, our results appear 
better than the 70% rate of SVR12 reported by Charlton [16] in a smaller series of 40 
patients recruited in a multicenter study, of whom only 40% were cirrhotics; possibly the 
management of the patients in a single center adopting a common approach may lead to 
more uniform results. Though our results are distinctly better than the 43% response 
reported by Forns et al [7], their series included a mixed population of compensated and 
decompensated cirrhotics in which a substantial number of patients had a higher MELD 
score and more severe disease than our patients.  
There were in our study six deaths due to complications of the liver disease, two occurring 
in patients who had cleared the HCV. The deceased patients had a higher MELD score, 
ranging from 14 to 19, in confirmation that a deteriorated liver function may prevent clinical 
improvement despite the antiviral efficacy of treatment [17]; vice versa a preserved liver 
function expressed by a Child Pugh score ≤6 and a MELD ≤11 was associated with SVR. 
Unfortunately, the threshold that may predict the lack of a clinical advantage despite the 
efficacy of therapy is difficult to establish [17].  
In our 72 cirrhotic responders, SVR24 was associated with the normalization of 
aminotransferases in almost all patients, accompanied by a decrease of bilirubin and an 
increase of albumin levels; renal function deteriorated in none and ascites disappeared in 
three quarters of cases. The platelet count increased throughout therapy, presumably 
related to the administration of epoetin and to an increased production of endogenous 
erythropoietin, secondary to ribavirin-induced anemia [18]. The platelet number diminished 
to baseline values at week 12 post-therapy, but then climbed back significantly at week 24 
and further increased at week 48; this trend and the regression of ascites may might be 
expression of an initial reduction in portal hypertension.     
The APRI and FIB-4 indexes significantly improved throughout the follow-up; as 
aminotransferases and platelets are major components for their calculation, the 
Page 39 of 49 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
improvement can be explained by the normalization of the enzymes and by the increase in 
the platelet count.  
Transient elastography LS values were significantly reduced at the 6th month of follow-up; 
this early improvement presumably resulted for a large extent byfrom the decrease of 
inflammation and edema which may artificially alter elastography. Interestingly, however, 
LS values showed a further significant decrease during the subsequent 6 month follow-up 
in patients with cirrhosis. Considering that artefacts due to liver inflammation could no 
longer be implicated, it is plausible that the observed continuing decrease of LS after the 
SVR24 corresponded to a genuine progressive reduction of fibrosis. In agreement with 
previous findings of fibrosis reversion in non-transplant patients with HCV cirrhosis who 
responded to interferon-therapy [19-21], our data would suggest that regression of fibrosis 
starts early and may become already measureable by transient elastography in the first 
year after therapy. 
In conclusion, our experience in a large single center LT cohort of advanced recurrent HCV 
disease, confirms the major therapeutic impact of sofosbuvir with ribavirin, extending also 
to difficult-to-treat genotype 3 patients. 
We acknowledge that a new wave of more efficacious DAA combinations is now available 
to treat hepatitis C [8, 15, 22]. Nevertheless, this study provides a paradigm of the 
excellent clinical outcome and of the potential for disease reversibility after that can be 
expected with successful DAA therapy in the transplant setting.  
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Table 1. Demographic and baseline characteristics of recipients and donors  
Recipient features (N=126) 
Age (years) 60 [54-66] 
Male 99 (78.6%) 
Body Mass Index (Kg/m
2
) 24.6 [22.5–26.9] 
25-OH vitamin D
^
 (<20 ng/mL) 71 (59.2%) 
HLA-DRB1*11 positive phenotype 34 (27.0%) 
IL28B genotype 
rs 12979860 C/C 
rs 8099917 T/T 
 
32 (25.4%) 
59 (46.8%) 
Previous antiviral treatment 
    Antiviral treatment after LT 
83 (65.9%) 
57 (45.2%) 
Immunosuppressive drug 
CsA – Tac – MMF – other 
 
50 (39.7%) – 56 (44.4%) – 56 (44.4%) – 5 (4.0%) 
Time since LT (years) 4.3 [2.3–7.2] 
HCV genotype 
1a - 1b - 1 (unspecified) 
2 - 3 – 4 
 
17 (13.5%) – 70 (55.6%) – 6 (4.8%) 
6 (4.8%) – 21 (16.7%) – 6 (4.8%) 
Baseline HCV RNA (log10 IU/mL) 
≥ 10
6
 IU/mL 
6.40 [6.10–6.66] 
101 (80.2%) 
Corresponding Metavir fibrosis stage 
F3 – F4 
 
30 (23.8%) – 96 (76.2%) 
Haemoglobin (g/dL) 12.8 [11.4–14.4] 
Platelets count (10
9
/L) 99 [67-140] 
Liver enzymes (IU/L) 
Aspartate aminotransferase 
Alanine aminotransferase 
γ-Glutamyltransferase 
 
60 [40-101] 
69 [45-116] 
75 [41-152] 
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Total bilirubin (mg/dL) 1.1 [0.7–1.8] 
INR 1.07 [0.98–1.22] 
Albumin (g/dL) 3.9 [3.6–4.3] 
eGFR* (mL/min) 70 [54-87] 
MELD score
§
 10 [8-13] 
Child class
§
 A – B – C 65 (67.7%) – 27 (28.1%) – 4 (4.2%) 
Ascites
§
 38 (39.6%) 
Encephalopathy
§
 12 (12.5%) 
Presence of varices
§
 26 (27.1%) 
Donor features (N=126) 
Age (years) 62 [50–71] 
Male 69 (54.8%) 
Split liver graft 2 (1.6%) 
Graft quality
^ 
suboptimal
#
 57 (47.5%) 
Cold ischemia time (minutes) 486 [424–545] 
Donor/Recipient match 
D-MELD 982 [666–1303] 
Numerical variables are expressed as median [Q1-Q3]. Categorical variables are expressed as 
numbers (prevalence, %). 
^6 missing data 
*Chronic Kidney Disease Epidemiology Collaboration equation 
§In 96 cirrhotic patients 
#According to Salizzoni et al, Transpl Int 2003 
Abbreviations: CsA, cyclosporine; D-MELD, donor age x recipient MELD; eGFR, estimated 
glomerular filtration rate; F, fibrosis; HCV, hepatitis C virus; HLA, human leukocyte antigen; 
IL28B, Interleukin 28B; LT, liver transplantation; MELD, Model for End-stage Liver Disease; MMF, 
mycophenolate mofetil; Tac, tacrolimus.  
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Table 2. Liver function tests and non-invasive markers of fibrosis at baseline and at 
the end of therapy in responder versus relapser cirrhotic patients 
 
BASELINE 
Responders  
(n=72) 
Relapsers  
(n=20) 
p
#
 
APRI 1.92 [1.00-3.27] 3.27 [1.72-5.51] 0.007 
FIB-4 5.95 [3.60-11.10] 8.45 [7.17-16.08] 0.009 
Liver stiffness* (kPa) 20.4 [16.0-33.8] 28.0 [21.6–44.4] 0.01 
Child score 5 [5-6] 7 [6-8] 0.002 
MELD score 10 [8-12] 13 [9-16] 0.02 
    
EOT 
Responders  
(n=72) 
Relapsers  
(n=20) 
p
#
 
APRI 0.46 [0.29-0.76] 0.83 [0.57-1.22] 0.02 
FIB-4 3.25 [1.90-4.30] 4.80 [3.71-7.42] 0.01 
Liver stiffness* (kPa) 17.5 [11.1-25.7] 23.4 [18.3-39.0] 0.09 
Child score 5 [5-6] 6 [5-7] 0.19 
MELD score 11 [9-14] 13 [11-17] 0.05 
Numerical variables are expressed as median [Q1-Q3] 
*Liver stiffness was available at baseline in 51 responders and 17 relapsers; at EOT in 51 responders and 13 
relapsers 
#
p-values calculated according to Wilcoxon test for paired data 
Abbreviations: APRI, AST to platelet ratio index; EOT, end of therapy; kPa, kilopascal; MELD, Model for End-
stage Liver Disease. 
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 Table 32. Clinical and biochemical variations in cirrhotic long-term 
responder cirrhotic patients who achieved viral eradication 
 
Baseline 
(N=72) 
EOT 
(N=72) 
SVR12 
(N=72) 
SVR24 
(N=72) 
SVR48 
(N=71°) 
p^ p
§
 
AST (IU/L) 69 [47-97] 23 [20-28] 27 [22-35] 24 [18-32] 21 [18-28] <0.001 0.13 
ALT (IU/L) 59 [41-90] 15 [11-23] 18 [14-27] 16 [12-25] 17 [12-27] <0.001 0.02 
Bilirubin (mg/dL) 1.1 [0.8-1.5] 1.4 [1.1-2.2] 0.9 [0.6-1.2] 0.8 [0.6-1.2] 0.9 [0.6-1.1] <0.001 0.74 
INR 
1.06                     
[0.99-1.20] 
1.11            
[1.07-1.24] 
1.09        
[1.02-1.24] 
1.08          
[1.02-1.22] 
1.11       
[1.07-1.23] 
0.03 0.007 
Albumin (g/dL) 3.9 [3.6-4.3] 4.1 [3.8-4.4] 4.1 [3.7-4.3] 4.2 [3.8-4.4] 4.3 [4.0-4.5] 0.02 0.31 
Creatinine (mg/dL) 1.1 [0.9-1.3] 1.1 [0.9-1.3] 1.0 [0.9-1.3] 1.1 [1.0-1.3] 1.1 [0.9-1.3] 0.36 0.12 
eGFR* (mL/min) 68 [52-84] 64 [52-80] 67 [53-83] 63 [52-78] 62 [52-82] 0.26 0.25 
Platelets (10
9
/L) 99 [65-134] 131 [86-185] 99 [64-133] 108 [72-142] 112 [68-144] 0.002 0.01 
Ascites 22 (30.6%) 12 (16.7%) 8 (11.1%) 7 (9.7%) 7 (9.9%) 0.003 >0.99 
Encephalopathy 5 (6.9%) 4 (5.6%) 3 (4.2%) 3 (4.2%) 2 (2.8%) 0.72 >0.99 
MELD score 10 [8-12] 11 [9-14] 9 [8-11] 9 [8-11] 10 [8-11] 0.34 0.92 
Child score 5 [5-6] 5 [5-6] 5 [5-6] 5 [5-5] 5 [5-5] <0.001 0.68 
Numerical variables are expressed as median [Q1-Q3]. Categorical variables are expressed as numbers 
(prevalence,%).  
p-values calculated according to Wilcoxon test for paired data for numerical variables and according to 
Fisher’s exact test for categorical variables. 
°71 out of 72 cured patients reached 48 weeks of follow-up after therapy 
*Chronic Kidney Disease Epidemiology Collaboration equation 
^Baseline versus SVR24 
§SVR24 versus SVR48 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular 
filtration rate; EOT, end of therapy; MELD, Model for End-stage Liver Disease; SVR12, sustained virological 
response at week 12 after end of therapy; SVR24, sustained virological response at week 24 after end of 
therapy; SVR48, sustained virological response at week 48 after end of therapy. 
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FIGURE LEGENDS 
 
Figure 1. Sustained virological response rates by intention to treat analysis 
according to fibrosis stage. SVR, sustained virological response; F, fibrosis according to 
Metavir; SVR12, sustained virological response at week 12 after therapy; SVR24, 
sustained virological response at week 24 after therapy. 
 
Figure 2. Sustained virological response rates at week 24 after therapy in the 96 
cirrhotic patients. SVR24, sustained virological response at week 24 after therapy; CI, 
confidence interval; IL28B, Interleukin 28B; HLA, human leukocyte antigen; TW4, week 4 
on therapy; MELD, Model for End-stage Liver Disease; APRI, AST to platelet ratio index; 
kPa, kilopascal. 
 
Figure 13. Variations of from baseline to weeks 24 and 48 after therapy in APRI 
(Panels A and B) and FIB-4 (Panels C and D) from baseline to weeks 24 and 48 after 
therapy, in F3 and F4 long-term responders. patients who achieved viral eradication. 
APRI, AST to platelet ratio index; F, fibrosis according to Metavir; SVR24, sustained 
virological response at week 24 after therapy; SVR48, sustained virological response at 
week 48 after therapy. 
 
Figure 24. Variations inof liver stiffness from baseline to weeks 24 and 48 after 
therapy in F3 (Panel A) and F4 patients (Panel B) who achieved viral 
eradicationlong-term responders. F, fibrosis according to Metavir; kPa, kilopascal; 
SVR24, sustained virological response at week 24 after therapy; SVR48, sustained 
virological response at week 48 after therapy. 
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Figure 1. Variations of APRI (Panels A and B) and FIB-4 (Panels C and D) from baseline to weeks 24 and 48 
after therapy, in F3 and F4 long-term responders. APRI, AST to platelet ratio index; F, fibrosis according to 
Metavir; SVR24, sustained virological response at week 24 after therapy; SVR48, sustained virological 
response at week 48 after therapy.  
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Figure 2. Variations of liver stiffness from baseline to weeks 24 and 48 after therapy in F3 (Panel A) and F4 
(Panel B) long-term responders. F, fibrosis according to Metavir; kPa, kilopascal; SVR24, sustained 
virological response at week 24 after therapy; SVR48, sustained virological response at week 48 after 
therapy.  
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